Rates and determinants of virologic and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice.

Rates and determinants of virologic and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice.

OBJECTIVE: To describe CD4 and HIV RNA changes during treatment resumption (TR) after treatment interruption (TI) compared with response to first highly active antiretroviral therapy (HAART) and to investigate predictors. METHODS: Using Concerted Action on SeroConversion to AIDS and Death in Europe...

Full description

Bibliographic Details
Main Authors:	Touloumi, G, Pantazis, N, Stirnadel, H, Walker, A, Boufassa, F, Vanhems, P, Porter, K
Format:	Journal article
Language:	English
Published:	2008

Similar Items

Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences.
by: Touloumi, G, et al.
Published: (2006)

The immunological and virological consequences of planned treatment interruptions in children with HIV infection
by: Klein, N, et al.
Published: (2013)

The immunological and virological consequences of planned treatment interruptions in children with HIV infection.
by: Nigel Klein, et al.
Published: (2013-01-01)

Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE collaboration.
by: Giota Touloumi, et al.
Published: (2013-01-01)

Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort.
by: Fidler, S, et al.
Published: (2007)

Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B.
by: Miriam Rosás-Umbert, et al.
Published: (2017-01-01)

Determinants of survival following HIV-1 seroconversion after the introduction of HAART.
by: Porter, K, et al.
Published: (2003)

Lopinavir/ritonavir as part of schemes of HAARt in HIV-positive pregnant women and women of reproductive age: the dynamics of clinical and immunological and virological indicators
by: A. B. Konkova-Reidman, et al.
Published: (2015-04-01)

Virological and immunological failure of HAART and associated risk factors among adults and adolescents in the Tigray region of Northern Ethiopia.
by: Genet Gebrehiwet Hailu, et al.
Published: (2018-01-01)

CMV retinitis in an HIV patient with clinical and immunological failure on HAART
by: Dipankar Chakraborty,, et al.
Published: (2015)

Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes.
by: Omar Sued, et al.
Published: (2015-01-01)

Virological remission after antiretroviral therapy interruption in female African HIV seroconverters
by: Gossez, M, et al.
Published: (2018)

Impaired CCR7 Expression on Plasmacytoid Dendritic Cells in HIV Infected Children on HAART With Virologic Failure
by: Pahwa Rajendra, et al.
Published: (2005-12-01)

Virologic and immunologic correlates of viral control after ART-interruption in SIV-infected rhesus macaques
by: M. Paiardini, et al.
Published: (2015-12-01)

Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD)
by: Oyomopito, R., et al.
Published: (2010)

Prevalence and Predictors of Immunological Failure among HIV Patients on HAART in Southern Ethiopia.
by: Kesetebirhan Delele Yirdaw, et al.
Published: (2015-01-01)

Determinants of periodontitis according to the immunological and virological profiles of HIV-infected patients in Yaoundé, Cameroon
by: Joseph Fokam, et al.
Published: (2020-12-01)

Neutralizing anti-Tat antibodies prolonged HAART interruption in vaccines in a prospective structured interruption study
by: Redfield Robert, et al.
Published: (2006-12-01)

Virologic and immunologic status of children with HIV-TB co-infections
by: Djatnika Setiabudi, et al.
Published: (2021-03-01)

Investigating the Use of Task Resumption Cues to Support Learning in Interruption-Prone Environments
by: Christina Schneegass, et al.
Published: (2021-12-01)

Immunologic and Virologic Progression in HIV Controllers: The Role of Viral "Blips" and Immune Activation in the ANRS CO21 CODEX Study.
by: Nicolas Noel, et al.
Published: (2015-01-01)

Determinants of Virological Failure in HIV Patients on Highly Active Antiretroviral Therapy (HAART): A Retrospective Cross-Sectional Study in the Upper East Region of Ghana
by: Abdulai Abubakari, et al.
Published: (2023-01-01)

Determinants of response to first HAART regimen in antiretroviral-naive patients with an estimated time since HIV seroconversion.
by: Thiébaut, R, et al.
Published: (2006)

HIV/HCV coinfection, HAART, and liver-related mortality.
by: Sabin, C, et al.
Published: (2004)

HIV-1 Virological Synapse is not Simply a Copycat of the Immunological Synapse.
by: Vasiliver-Shamis, G, et al.
Published: (2010)

HIV-1 Virological Synapse is not Simply a Copycat of the Immunological Synapse
by: Gaia Vasiliver-Shamis, et al.
Published: (2010-05-01)

Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection
by: Jintanat Ananworanich, et al.
Published: (2016-01-01)

Immuno-virological response and clinical outcome in naive elderly patients treated with antiretroviral therapy (HAART)
by: Palermo F, et al.
Published: (2010-05-01)

Pharmacology and immuno-virologic efficacy of once-a-day HAART in African HIV-infected children: ANRS 12103 phase II trial
by: Boubacar Nacro, et al.
Published: (2011-06-01)

Antiretroviral treatment interruption and resumption within 16 weeks among HIV-positive adults in Jinan, China: a retrospective cohort study
by: Jing Ma, et al.
Published: (2023-05-01)

Mutations Related to Antiretroviral Resistance Identified by Ultra-Deep Sequencing in HIV-1 Infected Children under Structured Interruptions of HAART.
by: Jose Manuel Vazquez-Guillen, et al.
Published: (2016-01-01)

Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection.
by: Fidler, S, et al.
Published: (2002)

Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection.
by: Fidler, S, et al.
Published: (2002)

Immunological and virological characterization of HIV-1 viremia controllers in the North Region of Brazil
by: Samara Tatielle M. Gomes, et al.
Published: (2017-06-01)

Immunological and virologic outcomes of people living with HIV in Guangxi, China: 2012-2017.
by: Xueying Yang, et al.
Published: (2019-01-01)

Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates.
by: Touloumi, G, et al.
Published: (2004)

Expression of type I interferon-associated genes at antiretroviral therapy interruption predicts HIV virological rebound
by: P. Zacharopoulou, et al.
Published: (2022-01-01)

Strategies for improving pediatric/adolescent HIV suppression rates for patients on HAART in Nigeria
by: A.V. Enejoh, et al.
Published: (2016-08-01)

A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes.
by: Michael H Chung, et al.
Published: (2011-03-01)

Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study.
by: Asier Sáez-Cirión, et al.
Published: (2013-03-01)